Cargando…

Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments

BACKGROUND: The conventional dose rate of radiation therapy is 0.01–0.05 Gy per second. According to preclinical studies, an increased dose rate may offer similar anti-tumoral effect while dramatically improving normal tissue protection. This study aims at evaluating the early toxicities for patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Doyen, Jérôme, Sunyach, Marie-Pierre, Almairac, Fabien, Bourg, Véronique, Naghavi, Arash O., Duhil de Bénazé, Gwenaëlle, Claren, Audrey, Padovani, Laetitia, Benezery, Karen, Noël, Georges, Hannoun-Lévi, Jean-Michel, Guedea, Ferran, Giralt, Jordi, Vidal, Marie, Baudin, Guillaume, Opitz, Lucas, Claude, Line, Bondiau, Pierre-Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842185/
https://www.ncbi.nlm.nih.gov/pubmed/33520724
http://dx.doi.org/10.3389/fonc.2020.613089
_version_ 1783643961375588352
author Doyen, Jérôme
Sunyach, Marie-Pierre
Almairac, Fabien
Bourg, Véronique
Naghavi, Arash O.
Duhil de Bénazé, Gwenaëlle
Claren, Audrey
Padovani, Laetitia
Benezery, Karen
Noël, Georges
Hannoun-Lévi, Jean-Michel
Guedea, Ferran
Giralt, Jordi
Vidal, Marie
Baudin, Guillaume
Opitz, Lucas
Claude, Line
Bondiau, Pierre-Yves
author_facet Doyen, Jérôme
Sunyach, Marie-Pierre
Almairac, Fabien
Bourg, Véronique
Naghavi, Arash O.
Duhil de Bénazé, Gwenaëlle
Claren, Audrey
Padovani, Laetitia
Benezery, Karen
Noël, Georges
Hannoun-Lévi, Jean-Michel
Guedea, Ferran
Giralt, Jordi
Vidal, Marie
Baudin, Guillaume
Opitz, Lucas
Claude, Line
Bondiau, Pierre-Yves
author_sort Doyen, Jérôme
collection PubMed
description BACKGROUND: The conventional dose rate of radiation therapy is 0.01–0.05 Gy per second. According to preclinical studies, an increased dose rate may offer similar anti-tumoral effect while dramatically improving normal tissue protection. This study aims at evaluating the early toxicities for patients irradiated with high dose rate pulsed proton therapy (PT). MATERIALS AND METHODS: A single institution retrospective chart review was performed for patients treated with high dose rate (10 Gy per second) pulsed proton therapy, from September 2016 to April 2020. This included both benign and malignant tumors with ≥3 months follow-up, evaluated for acute (≤2 months) and subacute (>2 months) toxicity after the completion of PT. RESULTS: There were 127 patients identified, with a median follow up of 14.8 months (3–42.9 months). The median age was 55 years (1.6–89). The cohort most commonly consisted of benign disease (55.1%), cranial targets (95.1%), and were treated with surgery prior to PT (56.7%). There was a median total PT dose of 56 Gy (30–74 Gy), dose per fraction of 2 Gy (1–3 Gy), and CTV size of 47.6 ml (5.6–2,106.1 ml). Maximum acute grade ≥2 toxicity were observed in 49 (38.6%) patients, of which 8 (6.3%) experienced grade 3 toxicity. No acute grade 4 or 5 toxicity was observed. Maximum subacute grade 2, 3, and 4 toxicity were discovered in 25 (19.7%), 12 (9.4%), and 1 (0.8%) patient(s), respectively. CONCLUSION: In this cohort, utilizing high dose rate proton therapy (10 Gy per second) did not result in a major decrease in acute and subacute toxicity. Longer follow-up and comparative studies with conventional dose rate are required to evaluate whether this approach offers a toxicity benefit.
format Online
Article
Text
id pubmed-7842185
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78421852021-01-29 Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments Doyen, Jérôme Sunyach, Marie-Pierre Almairac, Fabien Bourg, Véronique Naghavi, Arash O. Duhil de Bénazé, Gwenaëlle Claren, Audrey Padovani, Laetitia Benezery, Karen Noël, Georges Hannoun-Lévi, Jean-Michel Guedea, Ferran Giralt, Jordi Vidal, Marie Baudin, Guillaume Opitz, Lucas Claude, Line Bondiau, Pierre-Yves Front Oncol Oncology BACKGROUND: The conventional dose rate of radiation therapy is 0.01–0.05 Gy per second. According to preclinical studies, an increased dose rate may offer similar anti-tumoral effect while dramatically improving normal tissue protection. This study aims at evaluating the early toxicities for patients irradiated with high dose rate pulsed proton therapy (PT). MATERIALS AND METHODS: A single institution retrospective chart review was performed for patients treated with high dose rate (10 Gy per second) pulsed proton therapy, from September 2016 to April 2020. This included both benign and malignant tumors with ≥3 months follow-up, evaluated for acute (≤2 months) and subacute (>2 months) toxicity after the completion of PT. RESULTS: There were 127 patients identified, with a median follow up of 14.8 months (3–42.9 months). The median age was 55 years (1.6–89). The cohort most commonly consisted of benign disease (55.1%), cranial targets (95.1%), and were treated with surgery prior to PT (56.7%). There was a median total PT dose of 56 Gy (30–74 Gy), dose per fraction of 2 Gy (1–3 Gy), and CTV size of 47.6 ml (5.6–2,106.1 ml). Maximum acute grade ≥2 toxicity were observed in 49 (38.6%) patients, of which 8 (6.3%) experienced grade 3 toxicity. No acute grade 4 or 5 toxicity was observed. Maximum subacute grade 2, 3, and 4 toxicity were discovered in 25 (19.7%), 12 (9.4%), and 1 (0.8%) patient(s), respectively. CONCLUSION: In this cohort, utilizing high dose rate proton therapy (10 Gy per second) did not result in a major decrease in acute and subacute toxicity. Longer follow-up and comparative studies with conventional dose rate are required to evaluate whether this approach offers a toxicity benefit. Frontiers Media S.A. 2021-01-14 /pmc/articles/PMC7842185/ /pubmed/33520724 http://dx.doi.org/10.3389/fonc.2020.613089 Text en Copyright © 2021 Doyen, Sunyach, Almairac, Bourg, Naghavi, Duhil de Bénazé, Claren, Padovani, Benezery, Noël, Hannoun-Lévi, Guedea, Giralt, Vidal, Baudin, Opitz, Claude and Bondiau http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Doyen, Jérôme
Sunyach, Marie-Pierre
Almairac, Fabien
Bourg, Véronique
Naghavi, Arash O.
Duhil de Bénazé, Gwenaëlle
Claren, Audrey
Padovani, Laetitia
Benezery, Karen
Noël, Georges
Hannoun-Lévi, Jean-Michel
Guedea, Ferran
Giralt, Jordi
Vidal, Marie
Baudin, Guillaume
Opitz, Lucas
Claude, Line
Bondiau, Pierre-Yves
Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments
title Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments
title_full Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments
title_fullStr Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments
title_full_unstemmed Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments
title_short Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments
title_sort early toxicities after high dose rate proton therapy in cancer treatments
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842185/
https://www.ncbi.nlm.nih.gov/pubmed/33520724
http://dx.doi.org/10.3389/fonc.2020.613089
work_keys_str_mv AT doyenjerome earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT sunyachmariepierre earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT almairacfabien earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT bourgveronique earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT naghaviarasho earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT duhildebenazegwenaelle earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT clarenaudrey earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT padovanilaetitia earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT benezerykaren earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT noelgeorges earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT hannounlevijeanmichel earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT guedeaferran earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT giraltjordi earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT vidalmarie earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT baudinguillaume earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT opitzlucas earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT claudeline earlytoxicitiesafterhighdoserateprotontherapyincancertreatments
AT bondiaupierreyves earlytoxicitiesafterhighdoserateprotontherapyincancertreatments